Cargando…

Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity

PURPOSE: To describe the efficacy of intravitreal bevacizumab for the treatment of type 1 retinopathy of prematurity (ROP) in zone I. METHODS: Preterm infants with type 1 ROP in zone I (zone I ROP, any stage with plus disease or zone I ROP, stage 3 without plus disease) were enrolled in this prospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Karkhaneh, Reza, Torabi, Hamidreza, Khodabande, Alireza, Roohipoor, Ramak, Riazi-Esfahani, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5782452/
https://www.ncbi.nlm.nih.gov/pubmed/29403586
http://dx.doi.org/10.4103/jovr.jovr_198_16
_version_ 1783295196774006784
author Karkhaneh, Reza
Torabi, Hamidreza
Khodabande, Alireza
Roohipoor, Ramak
Riazi-Esfahani, Mohammad
author_facet Karkhaneh, Reza
Torabi, Hamidreza
Khodabande, Alireza
Roohipoor, Ramak
Riazi-Esfahani, Mohammad
author_sort Karkhaneh, Reza
collection PubMed
description PURPOSE: To describe the efficacy of intravitreal bevacizumab for the treatment of type 1 retinopathy of prematurity (ROP) in zone I. METHODS: Preterm infants with type 1 ROP in zone I (zone I ROP, any stage with plus disease or zone I ROP, stage 3 without plus disease) were enrolled in this prospective study. Intravitreal bevacizumab (0.625 mg/0.025 ml) was injected under topical anesthesia. Patients were followed weekly for 4 weeks and then biweekly till 90 weeks gestational age. RESULTS: Seventy eyes of 35 patients with type 1 ROP in zone I were enrolled. At a gestational age of 90 weeks, ROP regressed with complete or near-complete peripheral retinal vascularization, in 82.9% of eyes after a single injection and in 92.9% of eyes after up to two injections. In five eyes (7.1%), ROP progressed to stage 4B or 5, so surgical management was required. There were no major complications such as endophthalmitis, cataract, or vitreous hemorrhage after injection. CONCLUSION: Intravitreal bevacizumab injection is an effective method for the management of patients with Zone I ROP requiring treatment; however, some cases may progress to more advanced stages and require surgical management. Close monitoring for recurrence or progression is necessary. Eyes with persistent zone I ROP may progress to advanced stages when treated with intravitreal bevacizumab injection and re-treatment may be needed.
format Online
Article
Text
id pubmed-5782452
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-57824522018-02-05 Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity Karkhaneh, Reza Torabi, Hamidreza Khodabande, Alireza Roohipoor, Ramak Riazi-Esfahani, Mohammad J Ophthalmic Vis Res Original Article PURPOSE: To describe the efficacy of intravitreal bevacizumab for the treatment of type 1 retinopathy of prematurity (ROP) in zone I. METHODS: Preterm infants with type 1 ROP in zone I (zone I ROP, any stage with plus disease or zone I ROP, stage 3 without plus disease) were enrolled in this prospective study. Intravitreal bevacizumab (0.625 mg/0.025 ml) was injected under topical anesthesia. Patients were followed weekly for 4 weeks and then biweekly till 90 weeks gestational age. RESULTS: Seventy eyes of 35 patients with type 1 ROP in zone I were enrolled. At a gestational age of 90 weeks, ROP regressed with complete or near-complete peripheral retinal vascularization, in 82.9% of eyes after a single injection and in 92.9% of eyes after up to two injections. In five eyes (7.1%), ROP progressed to stage 4B or 5, so surgical management was required. There were no major complications such as endophthalmitis, cataract, or vitreous hemorrhage after injection. CONCLUSION: Intravitreal bevacizumab injection is an effective method for the management of patients with Zone I ROP requiring treatment; however, some cases may progress to more advanced stages and require surgical management. Close monitoring for recurrence or progression is necessary. Eyes with persistent zone I ROP may progress to advanced stages when treated with intravitreal bevacizumab injection and re-treatment may be needed. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC5782452/ /pubmed/29403586 http://dx.doi.org/10.4103/jovr.jovr_198_16 Text en Copyright: © 2018 Journal of Ophthalmic and Vision Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Karkhaneh, Reza
Torabi, Hamidreza
Khodabande, Alireza
Roohipoor, Ramak
Riazi-Esfahani, Mohammad
Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity
title Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity
title_full Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity
title_fullStr Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity
title_full_unstemmed Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity
title_short Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity
title_sort efficacy of intravitreal bevacizumab for the treatment of zone i type 1 retinopathy of prematurity
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5782452/
https://www.ncbi.nlm.nih.gov/pubmed/29403586
http://dx.doi.org/10.4103/jovr.jovr_198_16
work_keys_str_mv AT karkhanehreza efficacyofintravitrealbevacizumabforthetreatmentofzoneitype1retinopathyofprematurity
AT torabihamidreza efficacyofintravitrealbevacizumabforthetreatmentofzoneitype1retinopathyofprematurity
AT khodabandealireza efficacyofintravitrealbevacizumabforthetreatmentofzoneitype1retinopathyofprematurity
AT roohipoorramak efficacyofintravitrealbevacizumabforthetreatmentofzoneitype1retinopathyofprematurity
AT riaziesfahanimohammad efficacyofintravitrealbevacizumabforthetreatmentofzoneitype1retinopathyofprematurity